Stockreport

Sagimet: Positive Denifanstat Combination PK Data Could Lead To Untapped Market [Seeking Alpha]

Sagimet Biosciences Inc. - Series A  (SGMT) 
PDF SGMT's denifanstat plus resmetirom combo targets the untapped F4 MASH market, with phase 2 initiation anticipated in H2 2026 pending positive discussion with regulators [Read more]